Search
Bupivacaine
go.drugbank.com/drugs/DB00297ApprovedInvestigationalBupivacaine is a widely used local anesthetic agent.
Mixtures: BUPITROY® HEAVY 5 MG/ML, BUVACAINA® PESADA SOLUCION INYECTABLE 20 MG/ 4 MLCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEscitalopram
go.drugbank.com/drugs/DB01175ApprovedInvestigational[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting … that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: CIPRALEX 10 MG 56 TABLET, LEXAPRO 10 MGGranisetron
go.drugbank.com/drugs/DB00889ApprovedInvestigationalA serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Categories: Serotonin 5-HT3 Receptor Antagonists, Antiemetic Serotonin 5-HT3 Receptor AntagonistsProducts: NEOSET 1 MG FILM TABLET, 10 ADET, 10 ADET, SETRON 1 MG FILM TABLET, 10 ADETDabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalIt was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 SubstratesProducts: TAFINLAR 75 MG KAPSÜL ,120 ADET, TAFINLAR (CAPSULES 50 MG)Sapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationalessential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of tryptophan to 5-
Products: KUVAN 100 MG ÇÖZÜNEBİLİR TABLET, 30 ADET, KUVAN® 100 MGSecnidazole
go.drugbank.com/drugs/DB12834ApprovedInvestigationalSecnidazole is a second-generation 5-nitroimidazole antimicrobial agent. … Secnidazole is selective against many anaerobic Gram-positive and Gram-negative bacteria as well as protozoa.
Mixtures: GOTLAND CANDILOX 500/ 37.5 MG TABLETAS CUBIERTAS, FLUCONAZOL+SECNIDAZOL 75MG/1000 MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFluocortolone
go.drugbank.com/drugs/DB08971ApprovedWithdrawnFluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.
Mixtures: ULTRALAN POMAT, 10 GR, ULTRALAN POMAT, 20 GRCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersEpinastine
go.drugbank.com/drugs/DB00751ApprovedIt has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding
Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor AntagonistsProducts: FLURINOL COMPRIMIDOS RECUBIERTOS 10 MG., FLURINOL ® JARABE 0.2 G / 100 MLIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIt is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;[L12228] however, in
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: IMBRUVICA 140 MG SERT KAPSÜL ,90 KAPSÜL, IMBRUVİCA 140 MG FİLM KAPLI TABLET, 30 ADETBimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigationalIt has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug
Mixtures: BimatoTim-Vision 0,3 mg/ml + 5 mg/ml Augentropfen, Lösung, BEMATORİN-T 0,3 MG + 5 MG/1 ML GÖZ DAMLASI, ÇÖZELTİ, 1 ADETCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates